Mersana Therapeutics

Mersana Therapeutics is a leading clinical-stage biopharmaceutical company dedicated to developing innovative antibody-drug conjugates (ADCs) for cancer treatment. Driven by the imperative to provide new options for patients, Mersana Therapeutics focuses on creating impactful therapies that improve and extend lives. The company's proprietary Dolasynthen and Immunosynthen ADC platforms fuel a robust pipeline of both wholly-owned and partnered product candidates aimed at treating a diverse range of cancers.

Mersana Therapeutics is located at its primary address at 840 Memorial Drive, Cambridge, MA 02139, US. The company's commitment to advancing cancer therapeutics is exemplified by its pipeline, which includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana Therapeutics' pioneering research and development efforts position the company as a key player in the future of oncology treatments.

Mersana Therapeutics is rapidly advancing its ADC technology and expanding its therapeutic pipeline, promising significant advancements in cancer care. We invite the management team at Mersana Therapeutics to create a customized and exclusive company showcase and product listing on our platform to further highlight its groundbreaking work.